140 related articles for article (PubMed ID: 37276143)
1. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
[TBL] [Abstract][Full Text] [Related]
2. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract][Full Text] [Related]
3. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders.
Lei YH; Tang Q; Ni Y; Li CH; Luo P; Huang K; Chen X; Zhu YX; Wang NY
Bioorg Chem; 2024 May; 148():107427. PubMed ID: 38728911
[TBL] [Abstract][Full Text] [Related]
8. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
Yang L; Tu W; Huang L; Miao B; Kaneshige A; Jiang W; Leng L; Wang M; Wen B; Sun D; Wang S
J Med Chem; 2023 Aug; 66(15):10761-10781. PubMed ID: 37523716
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
10. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
Xiang Q; Wu T; Zhang C; Wang C; Xu H; Hu Q; Hu J; Luo G; Zhuang X; Wu X; Zhang Y; Xu Y
Bioorg Chem; 2024 Jan; 142():106950. PubMed ID: 37924753
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
[TBL] [Abstract][Full Text] [Related]
13. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
[TBL] [Abstract][Full Text] [Related]
14. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
15. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
[TBL] [Abstract][Full Text] [Related]
16. CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond.
Hu J; Xu Y
J Med Chem; 2024 Apr; 67(7):5272-5274. PubMed ID: 38517344
[TBL] [Abstract][Full Text] [Related]
17. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J; Chen Z; Qiao Y; Ching-Yi Tien J; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38586029
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
Strachowska M; Robaszkiewicz A
Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
[TBL] [Abstract][Full Text] [Related]
20. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
Qin C; Hu Y; Zhou B; Fernandez-Salas E; Yang CY; Liu L; McEachern D; Przybranowski S; Wang M; Stuckey J; Meagher J; Bai L; Chen Z; Lin M; Yang J; Ziazadeh DN; Xu F; Hu J; Xiang W; Huang L; Li S; Wen B; Sun D; Wang S
J Med Chem; 2018 Aug; 61(15):6685-6704. PubMed ID: 30019901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
